Clearpoint Neuro Congratulates Its Partner Aviadobio on First Patient Treated in Its Aspire-Ftd Clinical Trial Evaluating Avb-101 for Frontotemporal Dementia With Grn Mutations
Clearpoint Neuro祝贺其合作伙伴Aviadobio在评估Avb-101具有Grn突变的额睑痴呆的Aspire-Ftd临床试验中首次接受治疗的患者